Drug interactions
Sarilumab + Ublituximab
Severity: Moderate
Sarilumab and Ublituximab: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Both agents suppress immune function, sarilumab through IL-6 receptor blockade and ublituximab through B-cell depletion. Together they may increase the risk of serious infections.
What this interaction means in plain words
Sarilumab and Ublituximab can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Sarilumab belongs to Musculoskeletal; Ublituximab belongs to Miscellaneous.
Why it happens
Additive immunosuppression from IL-6 receptor antagonism and CD20-mediated B-cell depletion.
What to do
Screen for active or latent infection (including TB and hepatitis B) before use and monitor for infection signs; withhold therapy if a serious infection develops.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Sarilumab and Ublituximab, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Sarilumab
Other interactions of Ublituximab
Frequently asked questions
Can I take Sarilumab with Ublituximab?
MediHelp rates the interaction as moderate. Sarilumab and Ublituximab can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Both agents suppress immune function, sarilumab through IL-6 receptor blockade and ublituximab through B-cell depletion. Together they may increase the risk of serious infections.
How serious is the interaction between Sarilumab and Ublituximab?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Screen for active or latent infection (including TB and hepatitis B) before use and monitor for infection signs; withhold therapy if a serious infection develops.
What other medicines interact with Sarilumab?
MediHelp also lists interactions of Sarilumab with, for example, Adenovirus types 4 and 7 live, Bcg vaccine live, Dengue vaccine. The full list is on the Sarilumab page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
